---
schema_version: "secwatch.filing_event.v1"
accession: "0001824293-23-000145"
form_type: "8-K"
ticker: "GRI"
cik: "0001824293"
company_name: "GRI Bio, Inc."
filed_at: "2023-08-14T23:59:59+00:00"
generated_at: "2026-06-11T12:27:35.323753+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# GRI Bio reports Q2 net loss of $8.9M, cash $4.8M, Phase 2a IPF study on track for H2 2023

## Summary
- Net loss of $8.9M for six months ended June 30, 2023, primarily from increased R&D and G&A expenses.
- Cash and equivalents $4.8M at June 30, 2023; merger with Vallon Pharmaceuticals closed.
- R&D expenses Q2 2023: $0.9M (up from $0.1M); G&A $5.1M (up from $0.1M) due to merger costs.
- Phase 2a biomarker study for GRI-0621 in IPF on track to launch in H2 2023.
- IND-enabling studies for GRI-0803 in SLE ongoing; IND filing expected in H1 2024.

## SEC filing metadata
- accession: 0001824293-23-000145
- form_type: 8-K
- ticker: GRI
- cik: 0001824293
- company_name: GRI Bio, Inc.
- filed_at: 2023-08-14T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1824293/000182429323000145/0001824293-23-000145-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1824293/000182429323000145/val-20230814.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001824293-23-000145
- JSON: https://secwatch.observer/filing/0001824293-23-000145.json
- Plain text: https://secwatch.observer/filing/0001824293-23-000145.txt

## Key facts
- Earnings Releases
  GRI Bio, Inc. reported financial results for the quarter ended June 30, 2023.
  - Period: the quarter ended June 30, 2023
  - Result: reported results
  source text: On August 14, 2023, GRI Bio, Inc. (the Company) issued a press release announcing its financial results for the quarter ended June 30, 2023, and provided a business update.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1824293/000182429323000145/0001824293-23-000145-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.